ProQR Therapeutics N.V.
NASDAQ: PRQR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel Anton de Boer
- Employees
- 166
- Headquarters
- Leiden, Netherlands
- IPO year
- 2014
- Market cap
- $190.7M
- Website
- https://www.proqr.com
Loading PRQR…
Loading profile data…Frequently asked questions about PRQR
What does ProQR Therapeutics N.V. (PRQR) do?
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, tar...
Where does PRQR trade?
ProQR Therapeutics N.V. (PRQR) trades on the NASDAQ Global Market.
What sector is PRQR in?
ProQR Therapeutics N.V. (PRQR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ProQR Therapeutics N.V.?
Daniel Anton de Boer is the chief executive officer of ProQR Therapeutics N.V. (PRQR).
Where is ProQR Therapeutics N.V. headquartered?
ProQR Therapeutics N.V. is headquartered in Netherlands.
Does PRQR pay a dividend?
ProQR Therapeutics N.V. (PRQR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PRQR go public?
ProQR Therapeutics N.V. (PRQR) completed its initial public offering in 2014.